This article is more than 5 years old. Information may no longer be current.
Perioperative low-dose carperitide may play role in patients with renal dysfunction undergoing CABG
Sezai A. J Am Coll Cardiol. 2011;58:897-903.
Click Here to Manage Email Alerts
Perioperative low-dose carperitide showed renal protective effects on patients with chronic kidney disease undergoing CABG, according to a study.
In a randomized, double blind, placebo-controlled study, 285 patients with preoperative chronic kidney disease who underwent CABG surgery were split into two groups: 141 were assigned to the human atrial natriuretic peptide (hANP) group and received carperitide infusion, and 144 were assigned to a placebo group and received an infusion of physiological saline.
The postoperative dialysis rate was significantly lower in the hANP group, with only one patient requiring dialysis compared with eight patients in the placebo group. After discharge, one patient in the hANP group was placed on dialysis vs. five patients in the placebo group. There was a 98.6% dialysis-free rate at 1 year postoperatively in the hANP group vs. a 91.6% rate in the placebo group.
In early postoperative results, there were no in-hospital deaths in the hANP group, but four patients died in the placebo group. There were fewer complications in the hANP group. Only 10 patients had perioperative complications vs. 20 patients in the placebo group.
One patient in the hANP group and two patients in the placebo group died in the time period from discharge until 1 year postoperatively. Twenty-five patients in the hANP group had cardiac events vs. 55 in the placebo group. Researchers used the Kaplan-Meier method to determine overall survival rates of 99.3% in the hANP group and 95.8% in the placebo group, as well as cardiac event-free rates of 82.3% in the hANP group and 61.8% in the placebo group.
“This study demonstrated that infusion of carperitide in patients with preoperative chronic kidney disease undergoing CABG could improve renal function not only during the acute postoperative period but also up to 1 year postoperatively,” researchers wrote. “Carperitide is not considered to have any long-term pharmaceutical effects, but the cardiorenal protective effects of carperitide in the acute period are considered to result in good long-term effects.”
Disclosure: The researchers report no relevant financial disclosures.
 |
Follow CardiologyToday.com on Twitter. |